The stock's fall snapped a two-day winning streak.

No deal might be the best outcome for dividend-seeking investors. It’s a story as old as time. Two Dividend Aristocrats meet, ...

Personal healthcare products provider Kenvue Inc. (NYSE:KVUE) has been in the news for one reason or another recently.

Kenvue, Inc. (KVUE) has disclosed a new risk, in the Taxation & Government Incentives category. Kenvue, Inc. faces a significant risk if the ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company.

Along with OpenAI’s Amazon deal, Kimberly-Clark Corporation (NASDAQ:KMB) also made headlines after it announced that it would acquire household and personal products company Kenvue for $48.7 ...

U.S. futures followed global markets higher ahead of another big week of corporate earnings reports but an absence of economic data as the U.S. government shutdown entered its second month ...

Clorox stock is rated 'sell' amid weak growth, valuation concerns, and market challenges. Learn why fundamentals don't ...

Consumer giant Kimberly-Clark has agreed to buy Kenvue, the parent company of embattled brand Tylenol, for nearly $49 billion. But what does this mean for consumers and shareholders?

Yacktman Asset Management's Q3 2025 13F portfolio value declined to $7.26B, with 70 holdings and ~9% cash. Learn more about ...

Bank of America's stock has lagged behind rivals ... Lenders are increasing due diligence and demanding access to more data. Activist Investors in Kenvue Faced Big Losses. Kimberly-Clark Saved the Day ...